Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells

Hagen,Rachel M.; Chedea,Veronica S.; Mintoff,Christopher P.; Bowler,Elizabeth; Morse,H. Ruth; Ladomery,Michael R.

doi:10.3892/ijo.2013.1920

Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells

Authors:
- Rachel M. Hagen
- Veronica S. Chedea
- Christopher P. Mintoff
- Elizabeth Bowler
- H. Ruth Morse
- Michael R. Ladomery
View Affiliations

Affiliations: Centre for Research in Bioscience, Faculty of Health and Life Sciences, University of the West of England, Coldharbour Lane, Frenchay, Bristol BS16 1QY, UK
Published online on: April 24, 2013 https://doi.org/10.3892/ijo.2013.1920
Pages: 194-200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Growing evidence suggests that the flavonoid epigallocatechin-3-gallate (EGCG), notably abundant in green tea, has health-promoting properties. We examined the effect of EGCG on cell survival and apoptosis in the prostate cancer cell line PC3. Cell survival was reduced and apoptosis increased significantly with a low dose of 1 µM EGCG. The ability of the anticancer drug cisplatin to promote apoptosis was enhanced by EGCG. Furthermore, EGCG, both alone and in combination with cisplatin, promoted the expression of the pro-apoptotic splice isoform of caspase 9.

View Figures

View References

1.	Bettuzzi S, Brausi M, Rizzi F, Peracchia G and Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Am Assoc Cancer Res. 66:1234–1240. 2006.PubMed/NCBI
2.	Hsieh TC and Wu JM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein, and quercetin. Anticancer Res. 29:4025–4032. 2009.PubMed/NCBI
3.	Stuart Ec, Scandlyn MJ and Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci. 79:2329–2336. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Chen D and Dou QP: Tea polyphenols and their roles in cancer prevention and chemotherapy. Int J Mol Sci. 9:1196–1206. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Philips BJ, Coyle CH, Morrisroe SN, Chancellor MB and Yoshimura N: Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 30:207–215. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Manoharan M, Fatima I, Saxena R, Chandra V, Sankhwar PL and Dwivedi A: (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem. Sep 5–2012.(Epub ahead of print).
7.	Lim YC and Cha YY: Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. J Surg Oncol. 104:776–780. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D and Watanabe N: (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by downregulating survivin expression. Int J Oncol. 38:1403–1408. 2011.PubMed/NCBI
9.	Shen Q, Tian F, Jiang P, Li Y, Zhang L, Lu J and Li J: EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci. 29:771–775. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene. 27:2055–2063. 2007. View Article : Google Scholar
11.	Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, Ho CT and Way TD: (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem. 60:2480–2489. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Singh M, Singh R, Bhui K, Tyagi S, Mahmood Z and Shukla Y: Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer cells. Oncol Res. 19:245–257. 2011. View Article : Google Scholar
13.	Das A, Banik NL and Ray SK: Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer. 116:164–176. 2009.PubMed/NCBI
14.	Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, Yu A and Yang CS: Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gal-late in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis. 31:902–910. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Min NY, Kim JH, Choi JH, Liang W, Ko YJ, Rhee S, Bang H, Ham SW, Park AJ and Lee KH: Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biomed Biophys Res Commun. 421:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Markus MA, Marques FZ and Morris BJ: Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs. PLoS One. 6:e289262011. View Article : Google Scholar : PubMed/NCBI
17.	Anderson SL, Qiu J and Rubin BY: EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun. 310:627–633. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Kim MH: Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J Cell Biochem. 104:1491–1499. 2008.PubMed/NCBI
19.	David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Miura K, Fujibuchi W and Unno M: Splice variants in apoptotic pathway. Exp Oncol. 34:212–217. 2012.PubMed/NCBI
21.	Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD and Chalfant CE: Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 70:9185–9196. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A, Hawkins AJ, Mukerjee P, Pinkerman RL, Park MA and Chalfant CE: SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res. 9:889–900. 2011. View Article : Google Scholar
23.	Rasmussen R: Quantification on the LightCycler. Rapid Cycle Real-Time PCR, Methods and Applications. Meuer S, Wittwer C and Nakagawara K: Springer Press; Heidelberg: pp. 2001
24.	Applied Biosystems: Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR, 2008.
25.	Havsteen BH: The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 96:67–202. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Crespy V, Morand C, Manach C, Besson C, Demigne C and Remesy C: Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol. 277:G120–G126. 1999.PubMed/NCBI
27.	Pforte H, Hempel J and Jacobasch G: Distribution pattern of a flavonoid extract in the gastrointestinal lumen and wall of rats. Nahrung. 43:205–208. 1999. View Article : Google Scholar : PubMed/NCBI
28.	Albrecht DS, Clubbs EA, Ferruzzi M and Bomser JA: Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem Biol Interact. 171:89–95. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Yu HN, Shen SR and Yin JJ: Effects of interactions of EGCG and cd(2+) on the growth of PC-3 cells and their mechanisms. Food Chem Toxicol. 45:244–249. 2007.
30.	Caporali A, Davalli P, Astancolle S, D’Arca D, Brausi M, Bettuzzi S and Corti A: The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis. 25:2217–2224. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K and Kitajima M: Pharmacokinetics of cis-diamminedichloro-platinum (II) given as low-dose and high-dose infusions. J Surg Oncol. 62:135–138. 1996. View Article : Google Scholar : PubMed/NCBI
32.	Chan MM, Soprano KJ, Weinstein K and Fong D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol. 207:389–396. 2006. View Article : Google Scholar : PubMed/NCBI
33.	Yunos NM, Beale P, Yu JQ and Huq F: Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. Anticancer Res. 31:4283–4289. 2011.PubMed/NCBI
34.	Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H and Heber D: Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr. 136:1839–1843. 2006.PubMed/NCBI
35.	Rohde J, Jacobsen C and Kromann-Andersen H: Toxic hepatitis triggered by green tea. Ugeskr Laeger. 173:205–206. 2011.PubMed/NCBI
36.	Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y and Gupta KC: Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol. 7:2022011. View Article : Google Scholar : PubMed/NCBI
37.	Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li HZ, Lin HJ, Zhao Y, Wei M, Cheng K, Li LH, Dong H, Gao F, He JP, Wu Y, Qiu M, Zhao YL, Su JM, Hou JM and Liu JY: Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl). 89:595–602. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO and Ladomery MR: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20:768–780. 2011. View Article : Google Scholar : PubMed/NCBI